Treatment of Nocardia Chorioretinitis Related Choroidal Neovascularization with Aflibercept: A Case of Unveiled Immunocompromise with anti-GM-CSF Antibodies.

Q3 Medicine

Retinal Cases and Brief Reports Pub Date : 2024-08-02 DOI:10.1097/ICB.0000000000001646

Edward Korot, Katherine E Jaje, Neena Singhal, Maria C Miglio

{"title":"Treatment of Nocardia Chorioretinitis Related Choroidal Neovascularization with Aflibercept: A Case of Unveiled Immunocompromise with anti-GM-CSF Antibodies.","authors":"Edward Korot, Katherine E Jaje, Neena Singhal, Maria C Miglio","doi":"10.1097/ICB.0000000000001646","DOIUrl":null,"url":null,"abstract":"Purpose: The purpose of this study was to describe a case of Nocardia chorioretinitis-related choroidal neovascularization (CNV) in a patient with anti-GM-CSF antibodies with resolution of choroidal neovascularization and visual recovery following a series of intravitreal anti-vascular endothelial growth factor.Methods: This study is a case report.Results: In our case, a 50-year-old female, thought to be immunocompetent, presented with metamorphopsia and decreased visual acuity in the left eye in the setting of disseminated Nocardiosis. She had evidence of a subfoveal Nocardia lesion with subretinal fluid and CNV. Following a series of off-label injections with aflibercept, the patient had improvement in lesion size, exudation, and visual acuity. Extensive workup yielded underlying immunocompromise due to presence of anti-GM-CSF antibodies, likely predisposing her to disseminated Nocardiosis.Conclusion: The use of aflibercept in Nocardia chorioretinitis led to resolution of neovascular activity with visual recovery in a patient with disseminated Nocardiosis.","PeriodicalId":53580,"journal":{"name":"Retinal Cases and Brief Reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retinal Cases and Brief Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ICB.0000000000001646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The purpose of this study was to describe a case of Nocardia chorioretinitis-related choroidal neovascularization (CNV) in a patient with anti-GM-CSF antibodies with resolution of choroidal neovascularization and visual recovery following a series of intravitreal anti-vascular endothelial growth factor.

Methods: This study is a case report.

Results: In our case, a 50-year-old female, thought to be immunocompetent, presented with metamorphopsia and decreased visual acuity in the left eye in the setting of disseminated Nocardiosis. She had evidence of a subfoveal Nocardia lesion with subretinal fluid and CNV. Following a series of off-label injections with aflibercept, the patient had improvement in lesion size, exudation, and visual acuity. Extensive workup yielded underlying immunocompromise due to presence of anti-GM-CSF antibodies, likely predisposing her to disseminated Nocardiosis.

Conclusion: The use of aflibercept in Nocardia chorioretinitis led to resolution of neovascular activity with visual recovery in a patient with disseminated Nocardiosis.

查看原文本刊更多论文

用 Aflibercept 治疗诺卡氏脉络膜视网膜炎相关脉络膜新生血管：抗GM-CSF抗体揭示免疫功能低下的病例。

目的：本研究的目的是描述一例患有抗GM-CSF抗体的脉络膜新生血管（CNV）患者的诺卡氏菌脉络膜视网膜炎相关脉络膜新生血管（CNV），经过一系列玻璃体内抗血管内皮生长因子治疗后，脉络膜新生血管消退，视力恢复：本研究为病例报告：在我们的病例中，一名被认为免疫功能正常的 50 岁女性因患播散性诺卡地病而出现左眼变形和视力下降。她的视网膜下有诺卡氏菌病变，并伴有视网膜下积液和 CNV。在对患者进行了一系列阿夫利百普（aflibercept）标签外注射后，病变大小、渗出和视力均有所改善。广泛的检查结果显示，患者体内存在抗GM-CSF抗体，导致潜在的免疫功能低下，这很可能使她患上播散性诺卡氏病：结论：使用阿弗利百普治疗诺卡氏脉络膜视网膜炎可使一名播散性诺卡氏病患者的新生血管活动消退，视力恢复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊